tenecteplase 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
enzymes	5066	191588-94-0

Description:

Molecule

Description

Synonyms:

tenecteplase
metalyse
tnkase

A tissue plasminogen activator enzyme that acts as a fibrinolytic agent; it is used for the dissolution of blood clots, such as those that occur in acute MYOCARDIAL INFARCTION.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
40	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Feb. 23, 2001	EMA	BOEHRINGER INGELHEIM INTERNATIONAL GMBH
June 2, 2000	FDA	GENENTECH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral haemorrhage	95.50	62.23	27	590	30702	63457703
Haemorrhage intracranial	91.34	62.23	22	595	13397	63475008
Neurological decompensation	68.14	62.23	13	604	2625	63485780

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral haemorrhage	146.66	60.59	46	686	34891	34921308
Haemorrhage intracranial	83.65	60.59	25	707	15921	34940278

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral haemorrhage	226.70	51.92	69	1297	57604	79685418
Haemorrhage intracranial	163.55	51.92	45	1321	26148	79716874
Neurological decompensation	110.37	51.92	24	1342	5229	79737793
Cerebral infarction	73.23	51.92	28	1338	45648	79697374
Cerebral haematoma	60.51	51.92	16	1350	7926	79735096
Pericardial haemorrhage	58.99	51.92	14	1352	4481	79738541
Haemorrhagic transformation stroke	54.84	51.92	12	1354	2680	79740342
Subarachnoid haemorrhage	54.02	51.92	19	1347	24446	79718576
No adverse event	53.19	51.92	21	1345	37171	79705851

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B01AD11	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Enzymes
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D005343	Fibrinolytic Agents
MeSH PA	D006401	Hematologic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Ankylosing spondylitis	indication	9631008	DOID:7147
Acute myocardial infarction	indication	57054005	DOID:9408

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Plasminogen	Enzyme	P00747	PLMN_HUMAN	ACTIVATOR				DRUG LABEL	DRUG LABEL

External reference:

ID	Source
WGD229O42W	UNII
D06070	KEGG_DRUG
4021222	VANDF
C0872913	UMLSCUI
CHEMBL2108791	ChEMBL_ID
DB00031	DRUGBANK_ID
D000077785	MESH_DESCRIPTOR_UI
7769	INN_ID
259280	RXNORM
15637	MMSL
37705	MMSL
d04694	MMSL
008304	NDDF
127967007	SNOMEDCT_US
387066007	SNOMEDCT_US

Pharmaceutical products:

None